Clinical trials are expensive and resource-intensive, particularly when time is critical. Learn how we begin with the end in mind, focusing on clinical success from day one. Our suite of Clinical Trial Enabling Program streamlines the process from late-stage preclinical through to the IND process, focusing on rapid study start-up, fast-tracking the first patient in, and reducing time in trial initiation, ensuring your study is both efficient and cost-effective.
Leader in oncology research, Stephen Gately, PhD, President and CEO of TD2, and our team are dedicated to assuring your preclinical studies align with your project's success in the clinic. TD2 offers comprehensive preclinical, regulatory, and clinical services designed to support your compound through every phase of development.
